SSA
BMRN icon

Schonfeld Strategic Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Schonfeld Strategic Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-9,800
Closed -$867K – 1880
2023
Q3 		$867K Sell
9,800
-42,000
-81% -$3.74M 0.01% 1058
2023
Q2 		$200K Buy
+51,800
New +$4.87M ﹤0.01% 1572

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Schonfeld Strategic Advisors's BMRN Position: Q2 2026 in Review

Schonfeld Strategic Advisors opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 103,192 shares worth $5.9M. The stake represents 0.02% of the portfolio and ranks #583 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in BMRN as recently as Q4 2025.

Schonfeld Strategic Advisors first reported a position in BMRN in Q2 2016 and has held it in 29 quarters since. The position peaked at $25.7M in Q3 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Schonfeld Strategic Advisors held 103,192 shares of BioMarin Pharmaceuticals worth $5.9M as of Q2 2026.
  • BioMarin Pharmaceuticals was a new Schonfeld Strategic Advisors position in Q2 2026.
  • BioMarin Pharmaceuticals made up 0.02% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #583 holding.
  • Schonfeld Strategic Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2016 and has held it in 29 quarters since.
  • Schonfeld Strategic Advisors's BioMarin Pharmaceuticals position peaked at $25.7M in Q3 2025.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.